Active Biotech AB (BTPC) and Teva Pharmaceutical Industries Limited (TEVA) Release: Newly Published Phase 3 Exploratory Analysis Suggests Investigational Oral Laquinimod for Multiple Sclerosis May Reduce Brain Damage Caused by Neurodegeneration
10/1/2013 9:36:30 AM
Jerusalem & Lund, Sweden, October 1, 2013 - Teva Pharmaceutical Industries Ltd.
(NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today the
publication of a pre-planned analysis of the Phase III ALLEGRO study
demonstrating that once-daily oral laquinimod provides a beneficial impact on
brain tissue damage, one of the most destructive aspects of multiple sclerosis.
These data, "Placebo-controlled trial of oral laquinimod in multiple sclerosis:
MRI evidence of an effect on brain tissue damage," published online in September
by the Journal of Neurology, Neurosurgery & Psychiatry (JNNP), along with an
accompanying editorial titled, "Oral laquinimod for multiple sclerosis: beyond
the anti-inflammatory effect," can be found on the JNNP website at
Help employers find you! Check out all the jobs and post your resume.
comments powered by